Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Equity Average (2018 - 2025)

Neurogene (NGNE) has disclosed Equity Average for 5 consecutive years, with $269.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average rose 84.25% year-over-year to $269.4 million, compared with a TTM value of $269.4 million through Sep 2025, up 84.25%, and an annual FY2019 reading of $107.2 million, changed N/A over the prior year.
  • Equity Average was $269.4 million for Q3 2025 at Neurogene, down from $282.5 million in the prior quarter.
  • Across five years, Equity Average topped out at $301.1 million in Q1 2025 and bottomed at $146.2 million in Q3 2024.